Cancer vaccines targeting the HER2/neu oncogenic protein

Seminars in Oncology

Volumn 28, Issue 6 SUPPL. 18, 2001, Pages 12-20

  Disis, Mary L ^a   Schiffman, Kathy ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7.16.4; MONOCLONAL ANTIBODY HER2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; HELPER CELL; HUMAN; IMMUNE RESPONSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

EID: 0035683821     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.29721     Document Type: Review

References (42)

1. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. In vitro generation of human cytotoxic T-cells specific for peptides derived from the HER-2/neu proto-oncogene protein
4. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
5. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer
6. Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer
7. Immunity to oncogenic proteins
8. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
9. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients
10. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene
11. Oligopeptide induction of a cytotoxic T response to HER-2/neu proto-oncogene in vitro
12. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
13. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
14. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
15. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
16. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
17. Therapy with cultured T cells: Principles revisited
18. Requirement for recognition of class 11 molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL
19. Prevention of breast tumor development in vivo by down-regulation of the p185neu receptor
20. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer
21. Induction of anti-self-immunity to cure cancer
22. Dominance and crypticity of T cell antigenic determinants
23. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants
24. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein
25. HER-2/neu oncogenic protein: Issues in vaccine development
26. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
27. Increased vaccinespecific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
28. Immunosuppressive factors: Role in cancer development and progression
29. Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy
30. Constraints on CD4 recovery postchemotherapy in adults: Thymic insufficiency and apoptotic decline of expanded peripheral CD 4 cells
31. Delayed type hypersensitivity (DTH) response to recall antigens does not accurately reflect immune competence in advanced stage cancer patients
32. Seroconversion after influenza vaccination in patients with lung cancer
33. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
34. Elevated soluble c-erb-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
35. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
36. Peptides naturally presented by MHC class I molecules
37. + tumors
38. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides
39. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
40. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
41. + T cell help
42. + T lymphocytes following immunization with helper epitopes of HER-2/neu